Novo Nordisk Reports Results Of Phase 3a Trial Showed Semaglutide 2.4 mg Once-Weekly Subcutaneous As Adjunct To Intensive Behavorial Therapy Showed Significantly More Body Weight Loss vs Placebo Plus IBT